Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. The letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) on March 27, they said. Last month, the COVID-19 Working Group headed by Dr N K Arora had also recommended to the health ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who have been vaccinated with two doses of either Covishield or Covaxin. Covovax is manufactured through technology transfer from US-based vaccine maker Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was granted emergency-use listing by WHO on December 17, 2021. After Arvind Kejriwal’s tea invite, Himanta Biswa Sarma hits back Corruption in India, CBI and corruption, Fighting corruption in India, Corruption, Democracy, Justice, Central Bureau of Investigations, CBI, Black money, Benami properties, Forensic science, Cybercrime, Modern technologies, Political will, Policy paralysis, Reinforcing belief, India In August 2020, Novavax Inc. had announced a license agreement with the SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India, and low and middle-income countries.
Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults
